GlobeNewswire

Stratfor Launches Threat Lens 2.0 To Expand Corporate Insight Into Global Security Trends

Dela

Company to showcase platform innovations, including a customizable risk dashboard and real-time threat monitoring, at ASIS Europe 2018

 

AUSTIN, Texas, April 12, 2018 (GLOBE NEWSWIRE) -- Stratfor, the world's leading geopolitical intelligence platform, announced the launch of Threat Lens 2.0 to dramatically expand the global situational awareness of corporate security teams charged with ensuring the security of people, assets and other interests around the world. As the company's premier protective intelligence solution for globally engaged organizations, this latest release of Stratfor Threat Lens TM continues to help leaders better identify, anticipate, measure and mitigate risks that emerging threats pose to their operations. The latest Threat Lens platform enhancements and new features will be available for one-on-one demonstrations April 18-20 during ASIS Europe 2018 in Rotterdam, Netherlands.

"The response has been overwhelmingly positive since the launch of Stratfor Threat Lens and now, thanks to direct engagement and collaboration with our corporate security clients, we're excited to make this significant investment and build upon the value Threat Lens offers," said Stratfor President Chip Harmon. "This next generation Threat Lens platform delivers the customization, immediacy and the practical security context necessary for leaders of today's global enterprises to focus on what's most important to their organizations and make decisions with confidence."

New additions included in the launch of Threat Lens 2.0, Stratfor's award winning protective intelligence solution for global organizations, include:

  • A customizable Risk Dashboard, enabling clients to monitor the rise and fall of threat environment trends within a country of interest, coupled with the most recent intelligence threat updates.
  • A new Threat Monitoring map interface that highlights the locations and types of threats as they develop in real-time to enhance global situational awareness.
  • Significantly expanding the global reach and frequency of Intelligence Updates with immediate access to insight on emerging items of interest so corporate security teams can stay ahead of the news cycle and inform decision makers.

"For organizations with the responsibility to better protect their people and assets around the world, today's security professionals need to be proactive and constantly ahead of the curve so they can anticipate threats before they materialize," said Stratfor Vice President of Tactical Analysis Scott Stewart who will be presenting on Risk Mitigation and the Importance of Howat ASIS Europe on April 19. "Enhancements such as the customizable risk dashboard and new threat monitoring indices, that highlight the directionality of specific threat trends by country, give today's security professionals the edge they need."

Additional product advancements include a redesign of the global threat map to enable better access to Stratfor Threat Lens' in-depth analyses, the ability to personalize the user experience with custom options and more prominent alerts when incidents occur within a client's areas of interest. The upcoming Threat Lens API release will also enable even greater integration of Threat Lens analysis, alerts and other updates into existing client systems to allow faster, better informed responses to developing threats around the globe.

Corporate security teams and organizations with interests around the world rely on Stratfor Threat Lens to pinpoint which evolving global events are truly significant and it remains the only unified solution that integrates the full spectrum of security issues they face, spanning threats against people, infrastructure, intellectual property and business continuity. Advancements and expanded features included in the launch of Threat Lens 2.0 build upon the multi-layered analytical framework that has consistently and effectively allowed Stratfor analysts to evaluate the immediate significance and future implications of evolving situations so clients can anticipate threats and implement protective measures.

Stratfor analysts will demonstrate the latest developments with Threat Lens 2.0 at ASIS Europe (Booth A5) in Rotterdam, April 18-20. Corporate security leaders and others seeking to identify, anticipate, measure and mitigate risks that emerging threats pose to their people, assets and interests around the world can also learn more at Stratfor.com/threatlens.

About Stratfor
As the world's leading geopolitical intelligence platform,  Stratfor  brings global events into valuable perspective, empowering businesses, governments and individuals to more confidently navigate their way through an increasingly complex international environment.  Stratfor Threat Lens TM , a customizable, protective intelligence solution, helps corporate security leaders identify, anticipate, measure and mitigate risks that emerging threats pose to their people, assets and interests around the world. Learn more at  Stratfor.com .

Media Contact

Joshua Cook
Stratfor Director of Public Relations
512-744-4309
pr@stratfor.com

A photo accompanying this announcement is available at http://resource.globenewswire.com/Resource/Download/417d60ef-4fd2-426b-a07a-dc2f24a2caf3




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Stratfor Enterprises, LLC via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Investerarmöten våren 201915.2.2019 08:46:00Pressmeddelande

15 februari 2019 PRESSRELEASE Arcoma har som ambition att fortsätta öka sitt aktieägarfokus och kontinuerligt förbättra kommunikationen med aktieägare. Under våren 2019 kommer Arcoma medverka på flertalet investerarmöten där aktuella händelser och aktiviteter presenteras. Här ges en ökad inblick i bolagets vision och strategier samt en möjlighet till att ställa frågor till bolagets ledning. SvD Börsplus Temadag "Dubblare" Dag, tid och plats: 5 mars, kl. 13.00, GT 30, Grev Turegatan 30, Stockholm Stockholm Corporate Finance Life Science event Dag, tid och plats: 14 mars, kl. 07.30, Berns, Kammarsalen, Stockholm Redeyes Medtech & Diagnostics event Dag, tid och plats: 14:e maj, Redeye, Mäster Samuelsgatan 42, Stockholm För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soderqvist at arcoma.se Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalite

Corline Biomedical AB: Första patient doserad med Renaparin®15.2.2019 08:42:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man inkluderat första patienten i fas 1-studien RENAPAIR 01. Patienten inkluderades vid transplantationsavdelningen på Uppsala Akademiska sjukhus. Renaparin® är en produkt under utveckling för att förbättra njurtransplantation. I Corlines studie RENAPAIR 01 utvärderas produkten med avseende på tolerabilitet och säkerhet. Studien öppnades för patientrekrytering i slutet av 2018 och första patient är nu doserad och inkluderad i studien. Totalt skall 18 patienter rekryteras och när de 4 första patienterna är utvärderade i Uppsala, öppnas också Karolinska Universitetssjukhuset i Huddinge för rekrytering till studien. Henrik Nittmar, VD i Corline Biomedical AB, kommenterar "Det händer mycket i Corline för tillfället och alla arbetar hårt för att målbilden i bolaget skall uppfyllas. Det gäller såväl vår interna organisation som våra externa samarbetspartners. Därför är det extra roligt när vi når avgörande milstolpar i utvec

Corline Biomedical AB: Rekryterar Lars Olsson som Head of CMC14.2.2019 12:44:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man rekryterat Lars Olsson till den nyinrättade tjänsten som Head of CMC (Chemistry, Manufacturing & Control). Lars Olsson hade tidigare samma tjänst hos Wilson Therapeutics AB, som under 2018 förvärvades av amerikanska Alexion. Lars Olsson kommer att ansvara för Corlines samtliga aktiviteter inom tillverkning och kontroll relaterat till bolagets läkemedelsprodukter, med särskilt fokus på Renaparin® inför kommande fas 2- och fas 3-utveckling. I slutet av 2018 meddelade Corline att patientrekryteringen startar i bolagets fas 1-studie RENAPAIR 01, där produkten Renaparin®, som är under utveckling för att förbättra utfallet av njurtransplantation, utvärderas med avseende på tolerabilitet och säkerhet. Därmed tog en ny utvecklingsfas vid i bolaget i vilken alltmer resurser fokuseras på att förbereda den fortsatta kliniska utvecklingen av produkten genom fas 2 och fas 3 i syfte att slutligen kunna registrera produkten för k

Arcoma AB: Canon och Arcoma tecknar distributörsavtal för Turkiet14.2.2019 10:38:00Pressmeddelande

14 februari 2019 Canon Medical Systems i Turkiet och Arcoma har tecknat ett distributörsavtal som gör att Canon kommer att kunna sälja Arcomas produkter i Turkiet från och med den 15 februari 2019. Canon är sedan tidigare återförsäljare för Arcomas produkter i Nordamerika och utvalda länder i Europa. Detta samarbete utökas nu till Turkiet som är det första land i Canons Asien organisation att välja Arcoma som en formell partner. "Att vi stärker och formaliserar samarbetet med Canon även i Turkiet är ännu ett erkännande av Arcoma som leverantör av högkvalitativa röntgensystem. Canon i Turkiet förbereder ett flertal större upphandlingar till sjukhus där Arcomas lösningar ingår. Avtal som detta ingår i Arcomas strategi att utöka med nya försäljningskanaler och att expandera till nya länder för att skapa framtida tillväxt." kommenterar Arcomas VD, Jesper Söderqvist. För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soder

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum